Mylan introduces generic Clarinex tablets
Mylan Pharmaceuticals has introduced the generic version of Schering-Plough's Clarinex allergy medication, Desloratadine tablets, 5mg.
Mylan gained final FDA approval for its abbreviated new drug application for Desloratadine Tablets, 5mg, and is shipping the product immediately.
According to IMS Health, Desloratadine Tablets, 5mg, had US sales of approximately $194.6m for the 12 months ending 31 March2012.
At present, Mylan has 167 abbreviated new drug applications awaiting FDA approval representing $83.8bn in annual sales.
Thirty-seven of the pending ANDAs are potential first-to-file opportunities, representing $25.6bn in annual brand sales, for the 12 months ending 31 December 2011, according to IMS Health.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs